Prosecution Insights
Last updated: November 20, 2026
Application No. 18/265,855

A CELL CULTURE SYSTEM CONTROLLER

Non-Final OA §102§112
Filed
Jun 07, 2023
Priority
Dec 11, 2020 — GB 2019628.3 +1 more
Examiner
FISHER, BRITTANY I
Art Unit
1796
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Verso Biosense Group Limited
OA Round
2 (Non-Final)
84%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allowance Rate
459 granted / 544 resolved
+19.4% vs TC avg
Moderate +13% lift
Without
With
+12.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
44 currently pending
Career history
591
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
44.8%
+4.8% vs TC avg
§102
27.6%
-12.4% vs TC avg
§112
21.2%
-18.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 544 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, claims 1-9, 12, and 13 in the reply filed on March 26, 2026 is acknowledged. Claims 14-20 and 23-29 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on March 26, 2026. Drawings The drawings were received on June 7, 2023. These drawings are acceptable. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 7 and 12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. With respect to claim 7, the term “preferably” renders the clam indefinite because it is unclear whether the limitations following the phrase are part of the claimed subject matter. With respect to claim 12, the term “preferably” renders the clam indefinite because it is unclear whether the limitations following the phrase are part of the claimed subject matter. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1-9, 12, and 13 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Hansen et al (US 2017/0145372 A1) (provided by applicant in IDS dated 6/7/2023). With respect to claim 1 Hansen discloses a cell culture system controller (processing unit and memory, See Para. 0040; improved and programmable temperature control system described Paras. 0022 and 0029-0031) for controlling the environment of a cell culture system (incubator, See Fig. 5 and Paras. 0040-0043), the controller configured to receive intrauterine data and adjust one or more environmental parameters of a cell culture system environment over a period of time based on the intrauterine data (See Paras. 0028-0029 for discussion of how the incubator simulates the conditions in the uterus; a temperature control system is configured to provide the incubating chamber(s) with a predefined temperature profile, which optionally can be a profile with cyclic temperature variation, and where the cycle optionally can be repeated. In a further embodiment, the cyclic temperature profile can be set to simulate biological temperature variations, such as the daily variation known as the basal body temperature cycle). With respect to claim 2, Hansen discloses that the intrauterine data comprises monitored uterine conditions (See Para. 0028 for discussion of basal body temperature cycles being simulated). With respect to claim 3 Hansen discloses that the one or more environmental parameters are adjusted to replicate the environment of a single patient's uterus (See Para. 0031 for discussion of how the incubator comprises a plurality of incubating chambers that may be configured such that the temperature and cyclic temperature variation in each chamber can be controlled independently; the incorporation of separate chambers represents reducing the risk of cross contamination or mix up from patient to patient). With respect to claim 4 Hansen discloses that the period of time is at least 24 hours (See Para. 0030 for discussion of how a 24 hour cycle can be utilized). With respect to claim 5 Hansen discloses that the controller is configured to generate a time-dependent function based on the intrauterine data and wherein the one or more environmental parameters are adjusted according to the time-dependent function (See Para. 0030). With respect to claim 6 Hansen discloses that the profile of the time-dependent function is shaped to adjust the one or more environmental parameters to a maximum value and/or minimum value at least twice over the period of time (See Para. 0030). With respect to claim 7 Hansen discloses that the controller is configured to use the intrauterine data to adjust the temperature linearly between a first value at a first time and a second value at a second time, preferably wherein the first and second times are at least 12 hours apart, and more preferably at least 24 hours apart (See Para. 0030 for further discussion of how the temperature control system is configured to provide the incubating chamber(s) with a cyclic variation in temperature, controlled by a predefined maximum temperature (Tmax) and minimum temperature (Tmin), and a temperature ramp by piecewise linear changes defined by Tmax, Tmin, a start time and an end time for ramping, and with discrete incremental steps of 0.1°C; a temperature cycle is defined by 24 hours duration, Tmax, Tmin, and four predefined temperature change times, and wherein said cycle is repeated automatically). With respect to claim 8 Hansen discloses that the intrauterine data comprises at least two measurements of an environmental parameter (See Para. 0030 for further discussion of how the temperature control system is configured to provide the incubating chamber(s) with a cyclic variation in temperature, controlled by a predefined maximum temperature (Tmax) and minimum temperature (Tmin), and a temperature ramp by piecewise linear changes defined by Tmax, Tmin, a start time and an end time for ramping, and with discrete incremental steps of 0.1°C; An example of such a 24 hours cycle is illustrated in FIG. 1, where t1, t2, t3 and t4 indicate the predefined times for temperature changes). With respect to claim 9 Hansen discloses that the one or more environmental parameters are selected from: temperature, oxygen concentration, pH, pressure, light, humidity, a nutrient, a hormone, and a carbon dioxide concentration (See Para. 0030; also see Para. 0032 for discussion of the regulation of oxygen concentration inside an incubation chamber). With respect to claim 12 Hansen discloses that the controller is configured to receive intrauterine data and adjust two or more environmental parameters of the cell culture system environment over a period of time based on the intrauterine data, and preferably three or more environmental parameters (See Paras. 0018-19 and 0030-0032 for discussion of how the system adjusts temperature and oxygen and/or CO2 concentration over a specified period of time). With respect to claim 13 Hansen discloses that the cell culture system is configured to culture embryonic cells (See Para. 0016 for discussion of how the incubator is for incubating embryos). Applicant should note the italicized limitations are directed to the function of the apparatus and/or the manner of operating the apparatus. All the structural limitations of the claim have been disclosed by Hansen and the apparatus of Hansen is capable of the recitation of claim 13. As such, it is deemed that the claimed apparatus is not differentiated from the apparatus of Hansen (see MPEP §2114). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRITTANY I FISHER whose telephone number is (469)295-9182. The examiner can normally be reached IFP. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Lin can be reached at (571) 272-8902. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRITTANY I FISHER/Examiner, Art Unit 1796 April 18, 2026
Read full office action

Prosecution Timeline

Jun 07, 2023
Application Filed
Apr 30, 2026
Non-Final Rejection mailed — §102, §112
Aug 20, 2026
Examiner Interview Summary
Aug 20, 2026
Applicant Interview (Telephonic)
Aug 31, 2026
Response Filed
Nov 18, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12800471
CELL CAPTURE SYSTEM AND METHOD OF USE
4y 1m to grant Granted Nov 17, 2026
Patent 12789180
PIPETTE TIP
4y 7m to grant Granted Nov 10, 2026
Patent 12782370
GLOBAL TEST FOR DETERMINING THE STATUS OF THE BLOOD COAGULATION SYSTEM
3y 8m to grant Granted Nov 03, 2026
Patent 12768829
METHOD OF DETECTING THE PRESENCE OR ABSENCE OF A CLOT IN A LIQUID SAMPLE ANALYZER
4y 10m to grant Granted Oct 20, 2026
Patent 12768768
HIGH-EFFICIENCY OPTICAL DETECTION OF PARTICLES IN MICRO-CAPILLARIES
3y 9m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
84%
Grant Probability
97%
With Interview (+12.8%)
2y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 544 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month